Lamictal has a tolerability profile similar to placebo.

Lamictal is well tolerated, with no treatment-related changes in laboratory parameters or vital signs observed in the majority of studies. The type and frequency of adverse events after Lamictal treatment were usually comparable to placebo, with the exception of an increased incidence of headache in some studies. There was no difference between placebo and Lamictal in the number of patients withdrawing from studies due to adverse events. Although an increased incidence of rash has been reported in some trials, an analysis of 12 multicenter bipolar trials concluded that the rate of benign rash with Lamictal was less than 10%, which was similar to placebo. Proper dose titration can minimize the risk of rash.